CoChat

Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Pancreatic autoantibodies (PABs), comprising antibodies against glycoprotein 2 (anti-GP2), are typically associated with complicated phenotypes in Crohn's disease, but have also been observed with variable frequencies in patients with UC. In a previous study, we observed a high frequency of primary sclerosing cholangitis (PSC) in patients with anti-GP2-positive UC. We therefore aimed to characterise the role of anti-GP2 in PSC. DESIGN: In an evaluation phase, sera from 138 well-characterised Norwegian patients with PSC were compared with healthy controls (n=52), and patients with UC without PSC (n=62) for the presence of PABs by indirect immunofluorescence. Further, 180 German patients with PSC served as a validation cohort together with 56 cases of cholangiocarcinoma without PSC, 20 of secondary sclerosing cholangitis (SSC) and 18 of autoimmune hepatitis. RESULTS: Anti-GP2 IgA specifically occurred at considerable rates in large bile duct diseases (cholangiocarcinoma=36%, PSC and SSC about 50%). In PSC, anti-GP2 IgA consistently identified patients with poor survival during follow-up (Norwegian/German cohort: p Log Rank=0.016/0.018). Anti-GP2 IgA was associated with the development of cholangiocarcinoma in both PSC cohorts, yielding an overall OR of cholangiocarcinoma in patients with anti-GP2 IgA-positive PSC of 5.0 (p=0.001). Importantly, this association remained independent of disease duration, bilirubin level and age. CONCLUSIONS: Anti-GP2 IgA can be hypothesised as a novel marker in large bile duct diseases. In particular, in PSC, anti-GP2 IgA identified a subgroup of patients with severe phenotype and poor survival due to cholangiocarcinoma. Anti-GP2 IgA may therefore be a clinically valuable tool for risk stratification in PSC.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2016-311739

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 83

Metadata

Authors
Jendrek, S. T., Gotthardt, D., Nitzsche, T., Widmann, L., Korf, T., Michaels, M. A., Weiss, K.-H., Liaskou, E., Vesterhus, M., Karlsen, T. H., Mindorf, S., Schemmer, P., Bär, F., Teegen, B., Schröder, T., Ehlers, M., Hammers, C. M., Komorowski, L., Lehnert, H., Fellermann, K., Derer, S., Hov, J. R., & Sina, C.
Affiliations
  • University of Lübeck (DE)
  • University Hospital Heidelberg (DE)
  • Euroimmun Medizinische Labordiagnostika (Germany) (DE)
  • NIHR Birmingham Liver Biomedical Research Unit (GB)
  • Oslo University Hospital (NO)
Corresponding author
Sina, Christian
Venue
Gut
Publisher
BMJ
Published
2016-07-12
Volume
66
Issue
1
Pages
137-144
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2467158996
Cited by
83
References
38
Citations by year
2026: 8 · 2025: 9 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 2
FWCI
6.99
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
GP2, primary sclerosing cholangitis, cholangiocarcinoma, pancreatic autoantibodies, secondary sclerosing cholangitis, autoimmune hepatitis, survival, risk stratification, inflammatory bowel disease
MeSH terms
Adolescent, Adult, Aged, Autoantibodies, Bile Duct Neoplasms, Cell Transformation, Neoplastic, Colitis, Ulcerative, Female, Humans, Immunoglobulin A, Male, Middle Aged, Retrospective Studies, Risk Factors, Time Factors, Cholangitis, Sclerosing, Biomarkers, Survival Rate, Case-Control Studies, Cholangiocarcinoma, Hepatitis, Autoimmune, Young Adult, GPI-Linked Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1136/gutjnl-2016-311739
The paper
Jendrek, S. T., Gotthardt, D., Nitzsche, T., Widmann, L., Korf, T., Michaels, M. A., Weiss, K.-H., Liaskou, E., Vesterhus, M., Karlsen, T. H., Mindorf, S., Schemmer, P., Bär, F., Teegen, B., Schröder, T., Ehlers, M., Hammers, C. M., Komorowski, L., Lehnert, H., . . . Sina, C. (2017). Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. https://doi.org/10.1136/gutjnl-2016-311739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.